Shopping Cart 0
Cart Subtotal
USD 0

National Eye Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

National Eye Institute (NEI), a subsidiary of National Institutes of Health is a research institute that conducts research on human visual diseases and disorders. The institute provides education through National Eye Health Education Program such as diabetic eye disease education, glaucoma education, low vision education, and Spanish-language education. It performs research on visual disorders such as amblyopia, diabetic retinopathy, corneal stromal keratitis, age related mascular degeneration, cytomegalovirus, uneities, retinitis pigmentosa and lebers congenital amaurosis. NEI provides genetic resources and information for vision researchers, information on international research and stem cell research information and resources. The institute also include research division laboratories, section and units. NEI is based in Bethesda, Maryland, the US.

National Eye Institute-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

National Eye Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

National Eye Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

National Eye Institute, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 10

Foamix Enters into Co-Development Agreement with National Eye Institute 11

Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 12

National Eye Institute-Key Competitors 13

National Eye Institute-Key Employees 14

National Eye Institute-Locations And Subsidiaries 15

Head Office 15

Recent Developments 16

Government and Public Interest 16

Jun 21, 2018: Knights Templar Eye Foundation awards research grant to NEI scientist 16

Apr 28, 2018: Crinetics Pharmaceuticals Awarded NIH Phase-I SBIR Grant to Develop Somatostatin Receptor Agonist Drugs for Ophthalmic Diseases 17

Apr 13, 2018: Omega-3s from fish oil supplements no better than placebo for dry eye 18

Mar 21, 2018: Immune cells in the retina can spontaneously regenerate 20

Mar 16, 2018: Faculty Member to Study Eye Disease through New NIH Grant 22

Feb 01, 2018: Findings of Newly Discovered Positions in an Eye Genome Could Lead to New Treatments for Glaucoma 23

Jan 08, 2018: 3-D Mini Brains Accelerate Research for Repairing Brain Function 24

Jan 04, 2018: NEI-funded research suggests repetitive strain from eye movement may play a role in glaucoma 25

Jan 02, 2018: NIH discovery brings stem cell therapy for eye disease closer to the clinic 27

Nov 13, 2017: SUNY Downstate's Dr. Brahim Chaqour Receives USD 2 Million for Research Into Treatment of Incurable Vision-threatening Diseases 29

Nov 04, 2017: Enzyme identified as therapeutic target for ocular neovascularization 30

Oct 03, 2017: NIH Awards USD 2.4 Million to MPFI Scientist to investigate neural circuits in the visual cortex 31

Sep 26, 2017: National Eye Institute Awards USD 2.2m Grant For Jax Glaucoma Studies 32

Sep 10, 2017: USD 2.1M National Eye Institute grant funds JAX research in inherited retinal diseases 33

Jul 21, 2017: Wayne State Receives USD 1.9 million NIH Grant to Research and Find Treatments for Genetic Disease that causes Blindness 34

Jun 15, 2017: Wayne State receives USD 1.9 M NIH grant to develop novel therapy for corneal bacterial infection 35

May 08, 2017: Systemic therapy outperforms intraocular implant for treating uveitis 36

Mar 13, 2017: NIH-funded study helps explain how zebrafish recover from blinding injuries 37

Mar 08, 2017: Scientists Find Therapeutic Target for Diabetes-related Blindness 38

Jan 27, 2017: National Institutes of Health: Stem cell secretions may protect against glaucoma 39

Product News 40

Aug 16, 2018: NIH-funded study reverses congenital blindness in mice 40

Aug 15, 2018: NIH-funded researchers reverse congenital blindness in mice 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

National Eye Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

National Eye Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

National Eye Institute, Pharmaceuticals & Healthcare, Key Facts 2

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

National Eye Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

National Eye Institute, Deals By Therapy Area, 2012 to YTD 2018 8

National Eye Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 10

Foamix Enters into Co-Development Agreement with National Eye Institute 11

Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 12

National Eye Institute, Key Competitors 13

National Eye Institute, Key Employees 14

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

National Eye Institute, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

National Eye Institute (NEI), a subsidiary of National Institutes of Health is a research institute that conducts research on human visual diseases and disorders. The institute provides education through National Eye Health Education Program such as diabetic eye disease education, glaucoma education, low vision education, and Spanish-language education. It performs research on visual disorders such as amblyopia, diabetic retinopathy, corneal stromal keratitis, age related mascular degeneration, cytomegalovirus, uneities, retinitis pigmentosa and lebers congenital amaurosis. NEI provides genetic resources and information for vision researchers, information on international research and stem cell research information and resources. The institute also include research division laboratories, section and units. NEI is based in Bethesda, Maryland, the US.

National Eye Institute-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

National Eye Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

National Eye Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

National Eye Institute, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 10

Foamix Enters into Co-Development Agreement with National Eye Institute 11

Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 12

National Eye Institute-Key Competitors 13

National Eye Institute-Key Employees 14

National Eye Institute-Locations And Subsidiaries 15

Head Office 15

Recent Developments 16

Government and Public Interest 16

Jun 21, 2018: Knights Templar Eye Foundation awards research grant to NEI scientist 16

Apr 28, 2018: Crinetics Pharmaceuticals Awarded NIH Phase-I SBIR Grant to Develop Somatostatin Receptor Agonist Drugs for Ophthalmic Diseases 17

Apr 13, 2018: Omega-3s from fish oil supplements no better than placebo for dry eye 18

Mar 21, 2018: Immune cells in the retina can spontaneously regenerate 20

Mar 16, 2018: Faculty Member to Study Eye Disease through New NIH Grant 22

Feb 01, 2018: Findings of Newly Discovered Positions in an Eye Genome Could Lead to New Treatments for Glaucoma 23

Jan 08, 2018: 3-D Mini Brains Accelerate Research for Repairing Brain Function 24

Jan 04, 2018: NEI-funded research suggests repetitive strain from eye movement may play a role in glaucoma 25

Jan 02, 2018: NIH discovery brings stem cell therapy for eye disease closer to the clinic 27

Nov 13, 2017: SUNY Downstate's Dr. Brahim Chaqour Receives USD 2 Million for Research Into Treatment of Incurable Vision-threatening Diseases 29

Nov 04, 2017: Enzyme identified as therapeutic target for ocular neovascularization 30

Oct 03, 2017: NIH Awards USD 2.4 Million to MPFI Scientist to investigate neural circuits in the visual cortex 31

Sep 26, 2017: National Eye Institute Awards USD 2.2m Grant For Jax Glaucoma Studies 32

Sep 10, 2017: USD 2.1M National Eye Institute grant funds JAX research in inherited retinal diseases 33

Jul 21, 2017: Wayne State Receives USD 1.9 million NIH Grant to Research and Find Treatments for Genetic Disease that causes Blindness 34

Jun 15, 2017: Wayne State receives USD 1.9 M NIH grant to develop novel therapy for corneal bacterial infection 35

May 08, 2017: Systemic therapy outperforms intraocular implant for treating uveitis 36

Mar 13, 2017: NIH-funded study helps explain how zebrafish recover from blinding injuries 37

Mar 08, 2017: Scientists Find Therapeutic Target for Diabetes-related Blindness 38

Jan 27, 2017: National Institutes of Health: Stem cell secretions may protect against glaucoma 39

Product News 40

Aug 16, 2018: NIH-funded study reverses congenital blindness in mice 40

Aug 15, 2018: NIH-funded researchers reverse congenital blindness in mice 41

Appendix 42

Methodology 42

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

National Eye Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

National Eye Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

National Eye Institute, Pharmaceuticals & Healthcare, Key Facts 2

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

National Eye Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

National Eye Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

National Eye Institute, Deals By Therapy Area, 2012 to YTD 2018 8

National Eye Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Cellular Dynamics International Enters into R&D Agreement with National Eye Institute 10

Foamix Enters into Co-Development Agreement with National Eye Institute 11

Organovo Enters Into Co-Development Agreement With National Center For Advancing Translational Sciences And National Institutes of Health 12

National Eye Institute, Key Competitors 13

National Eye Institute, Key Employees 14

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

National Eye Institute, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.